Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis Chesler

Showing results (71-80 of 115) with videos related to

Pageof 12
Sort By:
Nature Communications|March 17, 2022
Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastomaAnke Nijhuis, Arti Sikka, Orli Yogev, et al.
Nature Genetics|January 31, 2018
Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastomaRhamy Zeid, Matthew A Lawlor, Evon Poon, et al.
Cancer Research|March 17, 2019
MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic TreatmentKonstantinos Zormpas-Petridis, Neil P Jerome, Matthew D Blackledge, et al.
European Journal of Cancer (Oxford, England : 1990)|June 4, 2016
Implementation of mechanism of action biology-driven early drug development for children with cancerAndrew D J Pearson, Ralf Herold, Raphaël Rousseau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 30, 2012
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugsMike I Walton, Paul D Eve, Angela Hayes, et al.
Oncotarget|January 18, 2018
Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumoursElisa Izquierdo, Lina Yuan, Sally George, et al.
Cancer Research|December 15, 2018
Macrophage-Derived IL1β and TNFα Regulate Arginine Metabolism in NeuroblastomaLivingstone Fultang, Laura D Gamble, Luciana Gneo, et al.
Cancer Cell|July 14, 2012
The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastomaTeeara Berry, William Luther, Namrata Bhatnagar, et al.
Genes & Development|May 19, 2010
Pleiotropic role for MYCN in medulloblastomaFredrik J Swartling, Matthew R Grimmer, Christopher S Hackett, et al.
Cancer Research|August 14, 2019
<i>In Vivo</i> Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and MetastasisOrli Yogev, Gilberto S Almeida, Karen T Barker, et al.
Pageof 12

Showing results (71-80 of 115) with videos related to

Sort By:
Pageof 12
Nature Communications|March 17, 2022
Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastomaAnke Nijhuis, Arti Sikka, Orli Yogev, et al.
Nature Genetics|January 31, 2018
Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastomaRhamy Zeid, Matthew A Lawlor, Evon Poon, et al.
Cancer Research|March 17, 2019
MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic TreatmentKonstantinos Zormpas-Petridis, Neil P Jerome, Matthew D Blackledge, et al.
European Journal of Cancer (Oxford, England : 1990)|June 4, 2016
Implementation of mechanism of action biology-driven early drug development for children with cancerAndrew D J Pearson, Ralf Herold, Raphaël Rousseau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 30, 2012
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugsMike I Walton, Paul D Eve, Angela Hayes, et al.
Oncotarget|January 18, 2018
Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumoursElisa Izquierdo, Lina Yuan, Sally George, et al.
Cancer Research|December 15, 2018
Macrophage-Derived IL1β and TNFα Regulate Arginine Metabolism in NeuroblastomaLivingstone Fultang, Laura D Gamble, Luciana Gneo, et al.
Cancer Cell|July 14, 2012
The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastomaTeeara Berry, William Luther, Namrata Bhatnagar, et al.
Genes & Development|May 19, 2010
Pleiotropic role for MYCN in medulloblastomaFredrik J Swartling, Matthew R Grimmer, Christopher S Hackett, et al.
Cancer Research|August 14, 2019
<i>In Vivo</i> Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and MetastasisOrli Yogev, Gilberto S Almeida, Karen T Barker, et al.
Pageof 12